Drug Trial Radar · NCT05033886
A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause
Last checked: Nov 20, 2026Latest source record: Oct 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
453
Actual
Start
Nov 8, 2021
Primary completion
Mar 27, 2023
Study completion Apr 20, 2023
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Sep 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 40 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is for women in menopause who have moderate to severe hot flashes. It is for women who are unable to use hormone replacement therapy (HRT). Menopause, a normal part of life, is the time after a woman's last period. Hot flashes often occur during menopause. They can disrupt a woman's daily life. The study medicines (also called investigational products, or IP) are tablets of fezolinetant or placebo. An investigational product means that the product is not yet licensed. In this study, a placebo is a dummy treatment that looks like fezolinetant but does not have any medicine in it. The study will compare fezolinetant with the placebo to learn if fezolinetant reduces the number and severity of hot flashes. Women that want to take part in the study will be given an electronic handheld device with an app to track their hot flashes. Some women may be able to use the app on their own smartphone. In the last 10 days before their next clinic visit, the women will record information about their hot flashes. They can take part in the study if they have an average of 7 or more moderate to severe hot flashes each day. Women will be picked for 1 of 2 treatments (fezolinetant or placebo) by chance alone. Women who take part in the study will take 2 tablets every day for 24 weeks. Treatment will be double-blinded. That means that the women in the study and the study doctors will not know who takes which of the study medicines (fezolinetant or placebo). The women will continue recording information about their hot flashes on the electronic device or their phone. They will also use another device to answer questions about how hot flashes affect their daily life. During the study, the women will visit their study clinic several times for a check-up. This will happen during Weeks 2, 4, 8, 12, 16, 20, 24, and 27. Some women may be able to have home visits instead, from Week 2 to Week 20. At the check-up, they will be asked if they have any medical problems. Other checks will include vital signs (heart rate, temperature and blood pressure) and some blood samples taken for laboratory tests. At some check-ups, the women will have a physical exam. In Week 2 and Week 24, the women will have an ECG to check their heart rhythm. Women who have a uterus will also have a test called a transvaginal ultrasound. A probe is gently placed inside the vagina. Sound waves will create a picture of the organs in the pelvis. This will allow the study doctor to look more closely at the uterus and surrounding organs. The last check-up (at Week 27) will be 3 weeks after they take their last tablets of study medicine (fezolinetant or placebo).
Conditions
- Vasomotor Symptoms
Interventions
fezolinetantDrug
oral
placeboDrug
oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change in the frequency of moderate to severe VMS from baseline at week 24Time frame: Baseline, week 24
Locations
69 sites in 16 countries. Site status is shown where the registry gives one.
Site BE32005
Tienen, Vlaams Brabant, Belgium
Site CA15002
Québec, Canada
Site CA15009
Québec, Canada
Site CA15007
Québec, Canada
Site CA15008
Brampton, Ontario, Canada
Site CA15010
London, Ontario, Canada
Site CA15003
Sarnia, Ontario, Canada
Site CA15012
Montreal, Quebec, Canada
Site CA15014
Québec, Quebec, Canada
Site CA15011
Saint Charles Borromeee, Quebec, Canada
Site CA15001
Sherbrooke, Quebec, Canada
Site CA15005
Victoriaville, Quebec, Canada
Site CZ42008
Brno, Czechia
Site CZ42010
České Budějovice, Czechia
Site CZ42005
Cheb, Czechia
Site CZ42009
Hradec Králové, Czechia
Site CZ42011
Náchod, Czechia
Site CZ42003
Olomouc, Czechia
Site CZ42004
Písek, Czechia
Site CZ42006
Prague, Czechia
Site CZ42007
Tábor, South Bohemian Region, Czechia
Site CZ42002
Vodňany, South Bohemian Region, Czechia
Site DK45005
Arhus C, Denmark
Site DK45003
Gandrup, North Denmark, Denmark
Site DK45002
Odense, Region Syddanmark, Denmark
Site DK45004
Vejle, Region Syddanmark, Denmark
Site FI35801
Kuopio, Finland
Site FI35803
Oulu, Finland
Site FR33003
La Rochelle, France
Site FR33001
Nantes, France
Site DE49004
Hamburg, Germany
Site DE49005
Hamburg, Germany
Site DE49002
Leipzig, Germany
Site DE49008
Muechen, Germany
Site DE49006
Schwerin, Germany
Site HU36002
Debrecen, Hungary
Site HU36004
Kecskemét, Hungary
Site HU36001
Szekesfeherver, Hungary
Site IT39002
Bologna, Italy
Site IT39006
Pavia, Italy
Showing 40 of 69 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.